KR102263038B1 - 암치료를 위한 adi-peg 20 항체에 대해 감소된 교차반응성을 지니는 아르기닌 탈이민효소 - Google Patents

암치료를 위한 adi-peg 20 항체에 대해 감소된 교차반응성을 지니는 아르기닌 탈이민효소 Download PDF

Info

Publication number
KR102263038B1
KR102263038B1 KR1020157024832A KR20157024832A KR102263038B1 KR 102263038 B1 KR102263038 B1 KR 102263038B1 KR 1020157024832 A KR1020157024832 A KR 1020157024832A KR 20157024832 A KR20157024832 A KR 20157024832A KR 102263038 B1 KR102263038 B1 KR 102263038B1
Authority
KR
South Korea
Prior art keywords
leu
glu
val
ile
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157024832A
Other languages
English (en)
Korean (ko)
Other versions
KR20150129728A (ko
Inventor
로버트 알마시
리차드 이 쇼월터
제임스 에이 톰슨
웨스 시손
웨이 종 시아
리 창 첸
양 리
Original Assignee
티디더블유 그룹
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 티디더블유 그룹 filed Critical 티디더블유 그룹
Priority to KR1020217016900A priority Critical patent/KR102455753B1/ko
Publication of KR20150129728A publication Critical patent/KR20150129728A/ko
Application granted granted Critical
Publication of KR102263038B1 publication Critical patent/KR102263038B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03006—Arginine deiminase (3.5.3.6)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020157024832A 2013-03-15 2014-03-13 암치료를 위한 adi-peg 20 항체에 대해 감소된 교차반응성을 지니는 아르기닌 탈이민효소 Active KR102263038B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020217016900A KR102455753B1 (ko) 2013-03-15 2014-03-13 암치료를 위한 adi-peg 20 항체에 대해 감소된 교차반응성을 지니는 아르기닌 탈이민효소

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361790833P 2013-03-15 2013-03-15
US61/790,833 2013-03-15
PCT/US2014/026766 WO2014151982A2 (en) 2013-03-15 2014-03-13 Arginine deiminase with reduced cross-reactivity toward adi – peg 20 antibodies for cancer treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217016900A Division KR102455753B1 (ko) 2013-03-15 2014-03-13 암치료를 위한 adi-peg 20 항체에 대해 감소된 교차반응성을 지니는 아르기닌 탈이민효소

Publications (2)

Publication Number Publication Date
KR20150129728A KR20150129728A (ko) 2015-11-20
KR102263038B1 true KR102263038B1 (ko) 2021-06-14

Family

ID=51581665

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020157024832A Active KR102263038B1 (ko) 2013-03-15 2014-03-13 암치료를 위한 adi-peg 20 항체에 대해 감소된 교차반응성을 지니는 아르기닌 탈이민효소
KR1020217016900A Active KR102455753B1 (ko) 2013-03-15 2014-03-13 암치료를 위한 adi-peg 20 항체에 대해 감소된 교차반응성을 지니는 아르기닌 탈이민효소

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020217016900A Active KR102455753B1 (ko) 2013-03-15 2014-03-13 암치료를 위한 adi-peg 20 항체에 대해 감소된 교차반응성을 지니는 아르기닌 탈이민효소

Country Status (12)

Country Link
US (2) US11235037B2 (cg-RX-API-DMAC7.html)
EP (2) EP3744341A1 (cg-RX-API-DMAC7.html)
JP (1) JP6382934B2 (cg-RX-API-DMAC7.html)
KR (2) KR102263038B1 (cg-RX-API-DMAC7.html)
CN (1) CN105188739B (cg-RX-API-DMAC7.html)
AU (1) AU2014236653B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015021483A2 (cg-RX-API-DMAC7.html)
CA (1) CA2901795C (cg-RX-API-DMAC7.html)
ES (1) ES2805360T3 (cg-RX-API-DMAC7.html)
RU (1) RU2015141932A (cg-RX-API-DMAC7.html)
SG (1) SG11201507354QA (cg-RX-API-DMAC7.html)
WO (1) WO2014151982A2 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014521602A (ja) 2012-04-04 2014-08-28 ポラリス グループ アルギニンデイミナーゼを用いる処置方法
WO2014151982A2 (en) 2013-03-15 2014-09-25 Polaris Group Arginine deiminase with reduced cross-reactivity toward adi – peg 20 antibodies for cancer treatment
WO2015143006A1 (en) * 2014-03-18 2015-09-24 Tdw Group Engineered chimeric pegylated adi and methods of use
TWI790481B (zh) 2014-07-08 2023-01-21 開曼群島商瑞華藥業集團 精胺琥珀酸合成酶之抗體及相關方法
CA2961602A1 (en) 2014-09-16 2016-03-24 Polaris Group Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment
TWI699210B (zh) * 2015-03-18 2020-07-21 開曼群島商瑞華藥業集團 工程化之嵌合聚乙二醇化adi及使用方法
US12281339B2 (en) 2016-07-05 2025-04-22 Polaris Group Combination cancer immunotherapies with arginine depletion agents
EP3534963B1 (en) 2016-11-02 2024-04-17 Polaris Group Formulations of pegylated arginine deiminase
WO2018167780A1 (en) * 2017-03-12 2018-09-20 Yeda Research And Development Co. Ltd. Methods of prognosing and treating cancer
US12344645B2 (en) * 2017-03-29 2025-07-01 Polaris Group Protein conjugates
CN108324951B (zh) * 2018-04-16 2021-05-25 薛剑峰 一种精氨酸脱亚胺酶注射剂及其制备方法
EP4580657A4 (en) * 2022-09-02 2026-02-18 Polaris Group Modified Arginine Deiminases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998051784A1 (en) 1997-05-12 1998-11-19 Phoenix Pharmacologics, Inc. Modiified arginine deiminase
WO2001083774A2 (en) 2000-05-04 2001-11-08 Phoenix Pharmacologics, Inc. Novel mutated form of arginine deiminase
US20090238813A1 (en) 2007-12-28 2009-09-24 Board Of Regents, The University Of Texas System Compositions And Methods For Engineered Human Arginine Deiminases
US20130052179A1 (en) 2011-08-22 2013-02-28 Yanshan HUANG Arginine deiminase mutant and preparation and application thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
JP2900279B2 (ja) 1989-08-02 1999-06-02 株式会社ジャパンエナジー 新規なアルギニンデイミナーゼ、その製造法及び該酵素を有効成分とする制癌剤
US5804183A (en) 1997-01-31 1998-09-08 Enzon, Inc. Arginine deminase derived from mycoplasma arthritidis and polymer conjugates containing the same
US6180387B1 (en) 1997-08-11 2001-01-30 Smithkline Beecham Corporation Arginine deiminase
IT1298918B1 (it) 1998-02-20 2000-02-07 Mendes Srl Uso di batteri dotati di arginina deiminasi per indurre apoptosi e/o ridurre una reazione infiammatoria e composizioni farmaceutiche
WO2002009741A1 (en) * 2000-07-27 2002-02-07 Angiolab, Inc. The pharmaceutical composition comprising arginine deiminase for inhibiting angiogenesis
AU2001289132A1 (en) 2000-11-28 2002-06-11 Phoenix Pharmacologics, Inc. Modified arginine deiminase
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
ES2477118T3 (es) * 2002-11-18 2014-07-15 Polaris Group Método para inhibir la replicaci�n viral in vivo
AU2004235382A1 (en) 2003-04-29 2004-11-11 Wyeth Methods for diagnosing AML and MDS differential gene expression
US20070212311A1 (en) 2003-10-07 2007-09-13 University Of Florida Research Foundation, Inc. Recombinant Alkalinizing Bacteria
CN101002945B (zh) 2006-01-20 2012-09-05 清华大学 一种用于肿瘤治疗的新型复合物
WO2009006590A2 (en) 2007-07-04 2009-01-08 Dr. Reddy's Laboratories Ltd. Docetaxel process and polymorphs
US20120015049A1 (en) 2009-01-14 2012-01-19 Lin Zhang Microrna biomarker in cancer
WO2011053871A2 (en) * 2009-10-30 2011-05-05 Life Technologies Corporation Multi-primer assay for mycoplasma detection
WO2011151704A2 (en) 2010-06-02 2011-12-08 Fresenius Kabi Oncology Ltd. Stable pharmaceutical compositions of rapamycin esters
WO2012075173A2 (en) 2010-12-01 2012-06-07 Board Of Regents The University Of Texas System Compositions and method for deimmunization of proteins
PL394618A1 (pl) 2011-04-19 2012-10-22 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Przeciwnowotworowe bialko fuzyjne
FR2978416B1 (fr) 2011-07-26 2013-11-29 Decathlon Sa Vehicule, par exemple du type trottinette, avec systeme de repliage
JP2014521602A (ja) 2012-04-04 2014-08-28 ポラリス グループ アルギニンデイミナーゼを用いる処置方法
WO2014151982A2 (en) 2013-03-15 2014-09-25 Polaris Group Arginine deiminase with reduced cross-reactivity toward adi – peg 20 antibodies for cancer treatment
WO2015143006A1 (en) 2014-03-18 2015-09-24 Tdw Group Engineered chimeric pegylated adi and methods of use
CA2961602A1 (en) 2014-09-16 2016-03-24 Polaris Group Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998051784A1 (en) 1997-05-12 1998-11-19 Phoenix Pharmacologics, Inc. Modiified arginine deiminase
WO2001083774A2 (en) 2000-05-04 2001-11-08 Phoenix Pharmacologics, Inc. Novel mutated form of arginine deiminase
US20090238813A1 (en) 2007-12-28 2009-09-24 Board Of Regents, The University Of Texas System Compositions And Methods For Engineered Human Arginine Deiminases
US20130052179A1 (en) 2011-08-22 2013-02-28 Yanshan HUANG Arginine deiminase mutant and preparation and application thereof

Also Published As

Publication number Publication date
US20140348814A1 (en) 2014-11-27
EP2968482A4 (en) 2016-07-20
KR20210069126A (ko) 2021-06-10
JP2016519069A (ja) 2016-06-30
US11235037B2 (en) 2022-02-01
US20220105160A1 (en) 2022-04-07
WO2014151982A2 (en) 2014-09-25
KR102455753B1 (ko) 2022-10-17
JP6382934B2 (ja) 2018-08-29
HK1219232A1 (zh) 2017-03-31
CA2901795A1 (en) 2014-09-25
CN105188739B (zh) 2017-06-23
WO2014151982A3 (en) 2015-01-08
EP2968482A2 (en) 2016-01-20
KR20150129728A (ko) 2015-11-20
EP2968482B1 (en) 2020-05-06
HK1214139A1 (en) 2016-07-22
EP3744341A1 (en) 2020-12-02
SG11201507354QA (en) 2015-10-29
CA2901795C (en) 2022-08-02
AU2014236653A1 (en) 2015-09-10
ES2805360T3 (es) 2021-02-11
RU2015141932A (ru) 2017-04-26
CN105188739A (zh) 2015-12-23
BR112015021483A2 (pt) 2017-10-10
AU2014236653B2 (en) 2019-04-18

Similar Documents

Publication Publication Date Title
KR102455753B1 (ko) 암치료를 위한 adi-peg 20 항체에 대해 감소된 교차반응성을 지니는 아르기닌 탈이민효소
JP6961061B2 (ja) 癌治療のためのadi−peg20抗体に対する交差反応性が低減したアルギニンデイミナーゼ
TWI676683B (zh) 用於癌症治療之對adi-peg20抗體交叉反應性降低之精胺酸去亞胺酶
HK40041474A (en) Arginine deiminase with reduced cross-reactivity toward adi-peg 20 antibodies for cancer treatment
HK40075284A (zh) 用於癌症治疗的对adi-peg20抗体具有降低的交叉反应性的精氨酸脱亚氨酶
HK1219232B (en) Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment
HK1214139B (en) Arginine deiminase with reduced cross-reactivity toward adi – peg 20 antibodies for cancer treatment

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 5